Venomics AI, a Bengaluru biotechnology startup spun out of the Indian Institute of Science (IISc), raised $2.7 million in a pre-seed funding round announced on November 5, 2026. The round was co-led by Speciale Invest and South Park Commons, with participation from Operators Studio. It is the company's first institutional funding round, coming about six months after it was founded in May 2026 by IISc professor Kartik Sunagar and Vinay Prabhu.
The funding will be used to expand the Venom Atlas, the company's growing molecular dataset, to strengthen its AI and laboratory screening capabilities, and to hire across venom biology, computational science, and drug discovery. The company has not disclosed a valuation, individual cheque sizes, target diseases, or a timeline for its first validated molecules.
Why venom is a drug discovery opportunity
Venom has been a source of medicines for decades, even though the idea still sounds exotic. The blood-pressure drug captopril was developed from a peptide found in the venom of the Brazilian pit viper. The diabetes and weight-loss drugs based on GLP-1 trace their origins to a compound in the saliva of the Gila monster, a venomous lizard. The painkiller ziconotide comes from the venom of a cone snail. In each case, evolution had already done the hard work: over millions of years, venomous animals evolved molecules precisely shaped to act on the nervous system, blood, and muscles of their prey.
That evolutionary refinement is what makes venom interesting to drug hunters. Venom molecules are typically potent, selective, and stable — the qualities a drug developer wants. The problem has always been the search. A single venom can contain hundreds of distinct molecules, and there are thousands of venomous species, from snakes and scorpions to spiders, cone snails, and jellyfish. Finding the handful of molecules with therapeutic potential, among millions of candidates, is a needle-in-a-haystack problem that traditional laboratory screening handles slowly and expensively.
Venomics AI's bet is that the combination of molecular sequencing, artificial intelligence, and laboratory testing can make that search systematic. Its platform sequences venoms to build the Venom Atlas, uses AI to rank the molecules most likely to become drug candidates, and then tests those predictions in its own laboratory.
What the money will fund
The uses of the funding describe a company at the data-building stage rather than the drug-testing stage. Expanding the Venom Atlas means sequencing more venoms and adding more molecular data. Strengthening AI and experimental screening means improving both the prediction models and the lab's ability to test predictions quickly. Hiring across research and computational science means building the team that can do both.
There is no molecule in a clinic here, and no drug candidate has been named. The company says it has put the initial architecture of its platform in place, and this cheque buys the next stage: data and proof. In the next year or so, the useful signals to watch are modest and checkable — how many molecules the atlas holds, how many candidates survive laboratory screening, and whether a pharmaceutical company or research body agrees to test any of them.
The Indian biotech context
Venomics AI is part of a wider pattern in Indian biotechnology: research spinning out of academic institutions into venture-backed companies. The Indian Institute of Science is one of India's leading research universities, and a spin-out led by a professor who is an expert in venom biology, paired with a co-founder bringing AI expertise, is a natural way to commercialise decades of academic work.
South Park Commons' involvement is notable. The fund, founded by Ruchi Sanghvi and Aditya Agarwal, backs founders at the earliest stages, including before they have a product, and runs a $40 million India fund led from Bengaluru by partner Prateek Mehta. Its participation, alongside specialist Indian deep-tech investor Speciale Invest, gives the company two kinds of backing: local expertise and an international network.
Why it matters for founders and investors
For founders, Venomics AI illustrates how a deep-tech company can be built from an unusual starting point. The insight is not a new app or a better workflow; it is that an underexplored natural resource — venom — combined with a general-purpose technology — AI — creates a search problem that is now tractable. Founders with domain expertise in an obscure field should take note: deep knowledge plus AI is currently one of the most fundable patterns in early-stage investing, precisely because the expertise is hard to replicate and the technology makes it newly productive.
For investors, the deal is a reminder that drug discovery is a long game, and that pre-seed biotech investing is a bet on a platform rather than a product. The risks are substantial. The science may not yield candidates that survive screening, and the candidates that survive may fail in animal or human testing. What the $2.7 million buys is the right to find out whether the platform works, and to generate the data that would justify a bigger bet.
Venom has already given medicine some of its most important drugs. Whether AI can turn that history into a systematic discovery engine is the question Venomics AI now has the funding to start answering.
Angeled.com connects founders with investors.
Sources: YourStory, November 5, 2026; Entrackr, November 5, 2026; Tech in Asia, November 5, 2026; Indian Startup News, November 5, 2026.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



